How forever chemicals target developing male brains — and what this means for their autism risk
Theories suggest this gender gap may be because male brains are more sensitive to changes during development, and girls might be better at hiding the signs or showing them in different ways.
Now, a new study published in the European Journal of Neuroscience has uncovered a shocking link between PFAS — also known as 'forever chemicals — and autism in men.
Scientists gave pregnant mice a type of short-chain PFAS called PFHxA — a chemical that's still widely used even though it's been restricted in some parts of the world.
The mothers were fed small doses, similar to what people might come across in their daily lives, and when their pups grew up, the male mice showed clear changes in behavior.
They were less active, more anxious and had trouble with memory, while the female mice didn't seem affected at all.
'Although these effects were mild, finding behavioral effects only in males was reminiscent of the many neurodevelopmental disorders that are male-biased,' Ania Majewska, a neuroscience professor at the University of Rochester, said in a press release.
'This finding suggests that the male brain might be more vulnerable to environmental insults during neurodevelopment.'
Until recently, PFHxA was considered a 'safer' replacement for older, more notorious forever chemicals that have been phased out.
But this study suggests we may have just swapped one problem for another — especially when it comes to protecting developing male brains.
'Finding that developmental exposure to PFHxA has long-term behavioral consequences in a mammalian model is concerning when considering short-chain PFAS are thought to be safer alternatives to the legacy PFAS that have been phased-out of production,' study lead author Elizabeth Plunk said.
'Understanding the impacts of PFHxA on the developing brain is critical when proposing regulations around this chemical. Hopefully, this is the first of many studies evaluating the neurotoxicity of PFHxA.'
The findings, while done on mice, suggest we need to take a closer scientific look at the link between forever chemicals and autism.
'This work points to the need for more research in short-chain PFAS. To our knowledge, PFHxA has not been evaluated for developmental neurobehavioral toxicity in a rodent model,' said Majewska. '
'Future studies should evaluate the cellular and molecular effects of PFHxA, including cell-type specific effects, in regions associated with motor, emotional/fear, and memory domains to elucidate mechanistic underpinnings.'
PFAS — synthetic substances that persist in the environment and human body — have been likened to 'slow poisons' that may increase the risk of certain cancers, fertility troubles, liver damage and developmental delays in children.
There are over 4,700 PFAS, which are used to make items resistant to water, grease and stains.
They can be found in food packaging, cookware, waterproof clothing, firefighting foam, certain personal care products and — most recently — beer.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Landmark Study Shows Ultromics' EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography
Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical. EchoGo® Amyloidosis is the first FDA-cleared AI screening tool for cardiac amyloidosis using an echocardiogram and has received Breakthrough Device designation from the FDA. Study results demonstrate accuracy of EchoGo® Amyloidosis in detecting cardiac amyloidosis, with strong performance across AL, ATTRwt, and ATTRv subtypes. OXFORD, England, July 9, 2025 /PRNewswire/ -- A large-scale, multi-center international study published in the European Heart Journal has shown that EchoGo® Amyloidosis, an AI-powered tool developed by Ultromics, significantly improves the screening of cardiac amyloidosis from a standard echocardiogram. It is the first FDA-cleared AI tool for this condition and has also received Breakthrough Device designation from the FDA. Researchers from Ultromics and Mayo Clinic, with investigators at The University of Chicago Medicine and collaborators around the world, validated and tested the model in a large and multiethnic patient population, and compared its performance to conventional diagnostic methods. The findings demonstrate that EchoGo® Amyloidosis is highly accurate, achieving 85% sensitivity and 93% specificity.1 The model performed consistently well across all major cardiac amyloidosis subtypes, and crucially distinguished the disease from phenotypically similar conditions such as hypertensive heart disease, HFpEF, and hypertrophic cardiomyopathy, conditions that often contribute to missed or delayed diagnosis.1 "EchoGo® Amyloidosis is a breakthrough tool that can help us identify at-risk patients so they can receive the treatment they need," said Ross Upton, CEO and Founder of Ultromics. "It uses deep learning to analyze a single routine echocardiography videoclip to deliver insights, helping clinicians decide when further investigation is needed. Early identification is critical in guiding access to therapies that are most effective when initiated at earlier stages of disease." Cardiac Amyloidosis: An Urgent Clinical Challenge Cardiac amyloidosis is a serious and often underdiagnosed cause of heart failure, driven by abnormal amyloid protein deposits, either light chain (AL) or transthyretin-derived (ATTRwt and ATTRv), that stiffen the heart and impair its function. Symptoms often mimic those of other cardiac conditions, making diagnosis challenging. As many as two-thirds of cases may be missed clinically. 2-4 Early diagnosis is crucial, as new drug therapies such as Tafamidis are now available that can slow or halt disease progression.5 The condition is especially difficult to identify in patients with heart failure with preserved ejection fraction (HFpEF), a common but diagnostically complex subtype of heart failure. Studies suggest that an estimated 15% of HFpEF patients may have underlying cardiac amyloidosis,6 a hidden burden that often goes unrecognized. Study Design and Key Findings The clinical study evaluating EchoGo® Amyloidosis followed a rigorous two-phase process: Development & Optimization Phase: Conducted at Mayo Clinic using 9,786 patients, including 1,349 biopsy-confirmed cardiac amyloidosis (CA) cases and 1,263 matched controls, to train and refine the deep learning model. External Validation Phase: Conducted across 2,719 patients at 18 global centers, where the AI was independently tested against gold-standard diagnostic criteria The external validation cohort included a broad range of institutions including The University of Chicago Medicine, Columbia University Irving Medical Center, Brigham and Women's Hospital, University of Pennsylvania, The Ohio State University Wexner Medical Center, University of Washington, Hospital of the University of Occupational and Environmental Health (Japan), Instituto do Coração – INCOR (Brazil), ICBA and Centro Privado de Cardiología (Argentina), The University of Texas MD Anderson Cancer Center, NorthShore University HealthSystem, University of Virginia Medical Center, Boston University, MedStar Health Research Institute, University of Leicester (UK), and Beth Israel Deaconess Medical Center. EchoGo® Amyloidosis was trained using apical 4-chamber echocardiographic video clips and validated against established diagnostic benchmarks, including biopsy and Tc-PYP imaging. The AI demonstrated high diagnostic performance, achieving 85% sensitivity and 93% specificity, indicating its ability to detect cardiac amyloidosis accurately from a single routine echocardiogram.1 EchoGo® Amyloidosis demonstrated strong performance across all major subtypes of cardiac amyloidosis, with sensitivities of 84% for AL, 85% for ATTRwt, and 86% for ATTRv. In a high-risk subgroup of HFpEF patients with increased wall thickness, EchoGo® Amyloidosis maintained strong diagnostic performance, demonstrating potential utility in one of the most diagnostically challenging settings in cardiovascular care.1 In comparative analysis, EchoGo® Amyloidosis outperformed two validated clinical scoring systems, the Transthyretin Cardiac Amyloidosis Score (TCAS) and the Increased Wall Thickness Score (IWT). The AI model demonstrated an AUC of 0.921, significantly exceeding TCAS (0.74) and IWT (0.80) in diagnostic accuracy.1 Decision curve analysis showed EchoGo® Amyloidosis identified 36.4% more true positive cases and reduced unnecessary referrals by 6.9% compared to the next best method.1 "EchoGo® Amyloidosis achieved high diagnostic accuracy across a broad spectrum of patients and clinical environments," said Patricia A. Pellikka, MD, Vice Chair, Department of Cardiovascular Medicine, Mayo Clinic, and senior author of the study. "In our subgroup analysis of older adults with HFpEF, where diagnosis is particularly challenging, the model not only maintained strong performance but also significantly outperformed traditional clinical and transthoracic echo-based screening methods. These results highlight its potential to improve early detection, reduce diagnostic uncertainty, and enhance patient care." "Current approaches to detecting cardiac amyloidosis on echocardiography often rely on markers that are either unreliable in contemporary clinical settings or time-consuming to implement consistently across high-volume echocardiography laboratories," said Jeremy A. Slivnick, MD, co-author and Assistant Professor at The University of Chicago Medicine. "With its ability to provide fully automated detection of cardiac amyloidosis using a single apical 4-chamber view, EchoGo® Amyloidosis offers a practical alternative that can be seamlessly integrated into routine workflows without compromising diagnostic performance." EchoGo® Amyloidosis is FDA-cleared and currently in use across multiple U.S. centers. It is part of Ultromics' growing AI portfolio, which also includes EchoGo® Heart Failure, an FDA-cleared device designed to aid in the detection of HFpEF, reimbursable under Medicare and commercial payer pathways, including Category III CPT Code 0932T for outpatient use and NTAP (XXE2X19) coverage for inpatient settings. Both tools operate through the EchoGo® platform, delivering diagnostic and clinical decision support from standard echocardiographic video clips, while integrating seamlessly into existing workflows to enable timely, informed care. Ultromics continues to advance the field of cardiovascular imaging by integrating AI and deep learning into everyday practice. Its mission is to support earlier detection, smarter triage, and broader access to therapies that are most effective when introduced at earlier stages of disease. Full study: About Ultromics Ultromics is a pioneering health technology company founded at the University of Oxford, dedicated to transforming cardiac care through AI-powered echocardiography. Its flagship product under the EchoGo® platform applies advanced artificial intelligence to routine ultrasound scans, helping clinicians detect heart disease earlier and more accurately, starting with HFpEF and cardiac amyloidosis. With multiple FDA-cleared solutions, including the first AI screening tool for cardiac amyloidosis, Ultromics is setting new standards for real-world clinical integration of AI in cardiovascular imaging. The company collaborates with world-leading institutions, including Mayo Clinic, Pfizer, and Janssen Biotech, Inc. (a Johnson & Johnson Company), to accelerate innovation and improve outcomes for patients globally. Learn more at Website: References [1] Slivnick, Hawkes et al., Eur Heart J (in press).[2] González-López E, et al., Eur Heart J. 2015;36:2585–94.[3] Hahn VS, et al., JACC Heart Fail. 2020;8:712–24.[4] AbouEzzeddine OF, et al., JAMA Cardiol. 2021;6:1267–74.[5] Maurer MS, et al., N Engl J Med 2018;379:1007–16.[6] Hahn VS et al, JACC Heart Fail. 2020;8:712–724. Photo: View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio
Yahoo
16 minutes ago
- Yahoo
Fungal infections are getting harder to treat
Fungal infections are getting harder to treat as they grow more resistant to available drugs, according to research published Wednesday in The Lancet Microbe. The study focused on infections caused by Aspergillus fumigatus, a fungus that is ubiquitous in soil and decaying matter around the world. Aspergillus spores are inhaled all the time, usually without causing any problems. But in people who are immunocompromised or who have underlying lung conditions, Aspergillus can be dangerous. The fungus is one of the World Health Organization's top concerns on its list of priority fungi, which notes that death rates for people with drug-resistant Aspergillus infections range from 47%-88%. The new study found that the fungus' drug resistance is increasing. On top of that, patients are typically infected with multiple strains of the fungus, sometimes with different resistance genes. 'This presents treatment issues,' said the study's co-author, Jochem Buil, a microbiologist at Radboud University Medical Centre in the Netherlands. Buil and his team analyzed more than 12,600 samples of Aspergillus fumigatus taken from the lungs of patients in Dutch hospitals over the last 30 years. Of them, about 2,000 harbored mutations associated with resistance to azoles, the class of antifungals used to treat the infections. Most of them had one of two well-known mutations, but 17% had variations of the mutations. Nearly 60 people had invasive infections — meaning the fungi spread from the lungs to other parts of the body — 13 of which were azole-resistant. In those people, nearly 86% were infected with multiple strains of the fungi, making treatment even more complicated. 'It is an increasingly complicated story and physicians may have trouble identifying whether or not they are dealing with a drug-resistant fungal infection,' said Dr. Arturo Casadevall, chair of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, who wasn't involved with the research. Before treating an Aspergillus fungal infection, doctors look for resistance genes that can give them clues about which drugs will work best. If someone is infected with multiple strains of the same type of fungus, this becomes much less clear-cut. Oftentimes, different strains will respond to different drugs. 'Azoles are the first line of treatment for azole-susceptible strains, but they do not work when a strain is resistant. For those, we need to use different drugs that don't work as well and have worse side effects,' Buil said, adding that some people will require treatment with multiple antifungal drugs at the same time. The findings illustrate a larger trend of growing pressure on the few drugs available to treat fungal infections — there are only three major classes of antifungal drugs, including azoles, that treat invasive infections, compared with several dozen classes of antibiotics. Resistance to such drugs is growing, and new ones are uniquely difficult to develop. Humans and fungi share about half of their DNA, meaning we're much more closely related to fungi than we are to bacteria and viruses. Many of the proteins that are essential for fungi to survive are also essential for human cells, leaving fewer safe targets for antifungal drugs to attack. 'The big problem for all of these fungal species is that we don't have a lot of antifungals,' said Jarrod Fortwendel, a professor of clinical pharmacy at the University of Tennessee Health Science Center, who was not involved with the research. 'Typically the genetic mutations that cause resistance don't cause resistance to one of the drugs, it's all of them, so you lose the entire class of drugs.' Further complicating matters, the vast majority of azole resistance in Aspergillus fumigatus stems from agriculture, which widely uses fungicides. The fungicides typically have the same molecular targets as antifungal drugs. Farmers spray them on crops, including wheat and barley in the U.S., to prevent or treat fungal disease. (The first instance of azole resistance was documented in the Netherlands, where antifungals are widely used on tulips.) Aspergillus fungi aren't the target, but exposure to the fungicides gives them a head start developing genes that are resistant to the targets, sometimes before an antifungal drug with the same target even hits the market. This was the source of the vast majority of the drug resistance analyzed in the study. Fortwendel noted that fungal resistance is increasingly found around the world. 'Basically everywhere we look for drug-resistant isotopes, we find them,' he said. 'We are seeing this azole drug-resistance happening throughout the U.S. Those rates will likely climb.' Any individual person's risk of having an azole-resistant Aspergillus fumigatus is low, Casadevall said. Infections typically affect people who are immunocompromised and amount to around a few thousand cases per year in the U.S., Casadevall said. While relatively uncommon, the bigger risk is the broader trend of drug-resistant fungal infections. 'The organisms that cause disease are getting more resistant to drugs,' he said. 'Even though it's not like Covid, we don't wake up to a fungal pandemic, this is a problem that is worse today than it was five, 10 or 20 years ago.' This article was originally published on


Hamilton Spectator
40 minutes ago
- Hamilton Spectator
AI tools and doctor shortage leading to rise in DIY diagnosis, Ontario docs say
TORONTO - The advent of AI and a lack of access to primary care are feeding a rising trend in people trying to diagnose and treat themselves online, doctors say. In an online media briefing hosted by the Ontario Medical Association on Wednesday, an endocrinologist, a cancer specialist and a psychiatrist all noted misinformation they frequently see online in their respective fields. The risks of DIY diagnosis include trying remedies posted on social media that are unsafe, delaying seeking legitimate medical treatment and being financially exploited by paying for things that don't work, they said. 'I foresee it continuing to happen more and more, especially with AI technology getting more and more available and more and more sophisticated,' said Dr. Valerie Primeau, a psychiatrist in North Bay, Ont. 'I have patients now that talk to ChatGPT to get advice.' Dr. Zainab Abdurrahman, a clinical immunologist and president of the OMA, said the fact that so many people don't have a family doctor leaves a void in places where patients can get trustworthy health information — so many turn to online and AI sources. 'One of the places where you have a lot of trust because you've had a long relationship is your family doctor. And that's something that you can feel comfortable to bounce some of these ideas by,' Abdurrahman said. 'When you don't have that, you're often feeling like you're going to all these other sources and you're not able to necessarily check the credibility for these resources.' Primeau said difficulty in accessing mental health care is another factor that drives people online and into potentially risky situations. 'The first concern obviously is misdiagnosis,' she said. 'When studies have looked at videos on social media, a lot of them are overly generalized, meaning they don't necessarily target a particular disorder, even though they say they do. They may portray inaccurately certain illnesses or provide misleading information.' That in turn can lead to dangerous attempts to self-treat, Primeau said. 'Some patients, for example, have reported to me trying a medication from a friend, a family member, because they believe they suffered from the same illness, and it's led to side effects.' Primeau said one of the most common trends she's seen is online tests that claim they can diagnose attention deficit hyperactivity disorder, or ADHD. 'If I ask everybody online today, 'have you ever been distracted or had trouble with organization or answering all your emails?' I think most people are going to say yes,' she said. 'There is a rising trend to self-diagnose with it because we recognize ourselves in the videos that are played about ADHD because in general, society is struggling with inattention.' True ADHD is a neurodevelopmental disorder, Primeau said, and can be traced back to childhood. Some mental health issues, such as anxiety and depression, are more likely to be correctly self-diagnosed by taking online tests, but should still be confirmed by a professional, she said. Other conditions are especially prone to being diagnosed incorrectly, including bipolar disorder, Primeau said. But going online to do mental health research is 'not all negative,' she said, noting that watching videos or listening to people talking about their illness and identifying with them can prompt patients to seek care for themselves. Social media groups can also offer peer support, she said. Primeau encourages patients to share what they find online with their health-care provider. 'Patients want to feel that they have a say in the decisions that you make with them,' she said. 'When they come (to) me with already some opinion about what they might be suffering from or their treatment, first of all, I take the information.' If the patient's research doesn't align with her professional diagnosis, Primeau has an open discussion with them and shows them evidence about why she came to that conclusion. If people don't have a family doctor, Abdurrahman of the OMA said other ways to access credible health knowledge include going to a walk-in clinic or checking the websites of established medical institutions and associations — but emphasized the need to solve the primary care shortage as a better solution. This report by The Canadian Press was first published July 9, 2025. Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.